- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA
This study is looking at a new combination of treatments for multiple myeloma that has come back or isn't responding to current treatments. It aims to find the safest dose of these new drugs and see how well they work together to shrink the cancer or stop it from growing.
For: CancerGreece · Germany · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors
This study is testing a new medicine, THOR-707, for people with advanced cancer. It aims to find the safest and most effective dose, and see how well it works alone or with other treatments to shrink tumours and improve health.
For: CancerSpain